Akkari and colleagues find that CD103+ regulatory T cells are highly abundant in the glioblastoma environment after checkpoint blockade restraining therapy response, and show therapeutic benefit for combined Treg targeting with radio-immunotherapy.
- Luuk van Hooren
- Shanna M. Handgraaf
- Leila Akkari
